Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma

被引:3
|
作者
Font, Albert [1 ,2 ]
de Porras, Vicenc Ruiz [2 ,3 ]
Valderrama, Begona P. [4 ]
Ramirez, Jose Luis [5 ]
Nonell, Lara [6 ]
Virizuela, Jose Antonio [7 ]
Anido, Urbano [8 ]
Gonzalez-del-Alba, Aranzazu [9 ]
Lainez, Nuria [10 ]
Llorente, Maria del Mar [11 ]
Jimenez, Natalia [12 ]
Mellado, Begona [13 ]
Garcia-Donas, Jesus [14 ]
Bellmunt, Joaquim [15 ]
机构
[1] Univ Hosp Germans Trias & Pujol, Catalan Inst Oncol, Dept Med Oncol, Ctr Can Ruti Cami Ies Escoles S-N, Badalona 08916, Spain
[2] Badalona Appl Res Grp Oncol B ARGO, Catalan Inst Oncol, Ctra Can Ruti Cami Escoles S-N, Badalona 08916, Spain
[3] Germans Trias & Pujol Res Inst IGTP, Ctra Can Ruti Cami Escoles S-N, Badalona 08916, Spain
[4] Hosp Univ Virgen Rocio, Dept Med Oncol, Seville 41013, Spain
[5] Univ Hosp Germans Trias & Pujol, Catalan Inst Oncol, Dept Haematol, Ctr Can Ruti Cami Escoles S-N, Badalona 08916, Spain
[6] Hosp Mar Med Res Inst IMIM, MARGen, Barcelona 08003, Spain
[7] Hosp Univ Virgen Macarena, Dept Med Oncol, Seville 41009, Spain
[8] Complejo Hosp Univ Santiago, Dept Med Oncol, Santiago De Compostela 15706, Spain
[9] Hosp Univ Puerta Hierro Majadahonda, Dept Med Oncol, Madrid 28222, Spain
[10] Complejo Hosp Navarra, Dept Med Oncol, Pamplona 31008, Spain
[11] Hosp Gen Univ Elda, Dept Med Oncol, Alicante 03600, Spain
[12] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona 08036, Spain
[13] Univ Barcelona, Hosp Clin Barcelona, Dept Med Oncol, IDIBAPS, Barcelona 08036, Spain
[14] HM Hosp Ctr Integral Oncol Hosp Madrid, Div Med Oncol, Madrid 28050, Spain
[15] Beth Israel Deaconess Med Ctr, Div Hematol & Oncol, Boston, MA 02215 USA
关键词
advanced urothelial cell carcinoma; vinflunine; chemotherapy resistance; epithelial-to-mesenchymal transition; maintenance therapy; SUPPORTIVE CARE; OPEN-LABEL; PHASE-III; LONG-TERM; CANCER; CHEMOTHERAPY; MULTICENTER; EXPRESSION; PLUS; ATEZOLIZUMAB;
D O I
10.3390/cancers13246235
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Platinum-based chemotherapy is the first-line treatment for advanced urothelial cell carcinoma (aUCC). After first-line treatment, we previously showed that maintenance therapy with vinflunine improves progression-free survival. However, some patients are resistant to vinflunine and the specific mechanisms of resistance in aUCC are unclear. We analyzed the genomic landscape and the biological processes potentially related to vinflunine activity and found that epithelial-to-mesenchymal transition (EMT) plays a pivotal role as a resistance mechanism. In experiments with cell lines, curcumin reversed EMT and sensitized cells to vinflunine. We suggest that EMT mediates resistance to vinflunine and that the reversion of this process could enhance the effect of vinflunine in aUCC patients. In the phase II MAJA trial, maintenance therapy with vinflunine resulted in longer progression-free survival compared to best supportive care in advanced urothelial cell carcinoma (aUCC) patients who did not progress after first-line platinum-based chemotherapy. However, despite an initial benefit observed in some patients, unequivocal resistance appears which underlying mechanisms are presently unknown. We have performed gene expression and functional enrichment analyses to shed light on the discovery of these underlying resistance mechanisms. Differential gene expression profile of eight patients with poor outcome and nine with good outcome to vinflunine administered in the MAJA trial were analyzed. RNA was isolated from tumor tissue and gene expression was assessed by microarray. Differential expression was determined with linear models for microarray data. Gene Set Enrichment Analysis (GSEA) was used for the functional classification of the genes. In vitro functional studies were performed using UCC cell lines. Hierarchical clustering showed a differential gene expression pattern between patients with good and poor outcome to vinflunine treatment. GSEA identified epithelial-to-mesenchymal transition (EMT) as the top negatively enriched hallmark in patients with good outcome. In vitro analyses showed that the polyphenol curcumin downregulated EMT markers and sensitized UCC cells to vinflunine. We conclude that EMT mediates resistance to vinflunine and suggest that the reversion of this process could enhance the effect of vinflunine in aUCC patients.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma
    Mir, Nabiel
    Jayachandran, Aparna
    Dhungel, Bijay
    Shrestha, Ritu
    Steel, Jason C.
    CURRENT CANCER DRUG TARGETS, 2017, 17 (08) : 698 - 706
  • [2] The Role of Epithelial-to-Mesenchymal Transition in Cutaneous Squamous Cell Carcinoma Epithelial-to-Mesenchymal Transition in Cutaneous SCC
    Fernandez-Figueras, Maria-Teresa
    Puig, Luis
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (06)
  • [3] Epithelial-to-Mesenchymal Transition in Penile Squamous Cell Carcinoma
    Masferrer, Emili
    Ferrandiz-Pulido, Carla
    Masferrer-Niubo, Magali
    Rodriguez-Rodriguez, Alfredo
    Gil, Inmaculada
    Pont, Antoni
    Servitje, Octavi
    de Herreros, Antonio Garcia
    Lloveras, Belen
    Garcia-Patos, Vicenc
    Pujol, Ramon M.
    Toll, Agusti
    Hernandez-Munoz, Inmaculada
    JOURNAL OF UROLOGY, 2015, 193 (02): : 699 - 705
  • [4] Epithelial-to-mesenchymal transition and its clinicopathological implications in patients with urothelial carcinoma of the bladder
    Garg, M.
    CANCER MEDICINE, 2018, 7 : 17 - 18
  • [5] Epithelial-to-Mesenchymal Transition and Neoangiogenesis in Laryngeal Squamous Cell Carcinoma
    Franz, Leonardo
    Nicole, Lorenzo
    Frigo, Anna Chiara
    Ottaviano, Giancarlo
    Gaudioso, Piergiorgio
    Saccardo, Tommaso
    Visconti, Francesca
    Cappellesso, Rocco
    Blandamura, Stella
    Fassina, Ambrogio
    Marioni, Gino
    CANCERS, 2021, 13 (13)
  • [6] Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma
    Marijon, Helene
    Dokmak, Safi
    Paradis, Valerie
    Zappa, Magaly
    Bieche, Ivan
    Bouattour, Mohamed
    Raymond, Eric
    Faivre, Sandrine
    JOURNAL OF HEPATOLOGY, 2011, 54 (05) : 1073 - 1078
  • [7] Epigenetics of epithelial-to-mesenchymal transition in pancreatic carcinoma
    Traeger, Max M.
    Dhayat, Sameer A.
    INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (01) : 24 - 32
  • [8] Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
    Marin-Aguilera, Mercedes
    Codony-Servat, Jordi
    Reig, Oscar
    Jose Lozano, Juan
    Luis Fernandez, Pedro
    Veronica Pereira, Maria
    Jimenez, Natalia
    Donovan, Michael
    Puig, Pere
    Mengual, Lourdes
    Bermudo, Raquel
    Font, Albert
    Gallardo, Enrique
    Jose Ribal, Maria
    Alcaraz, Antonio
    Gascon, Pere
    Mellado, Begona
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (05) : 1270 - 1284
  • [9] Effects of cisatracurium on epithelial-to-mesenchymal transition in esophageal squamous cell carcinoma
    Lv, Wenyan
    Wang, Jingyu
    Zhang, Shubao
    ONCOLOGY LETTERS, 2019, 18 (05) : 5325 - 5331
  • [10] Epithelial-to-mesenchymal transition in oral squamous cell carcinoma: Challenges and opportunities
    Ling, Zihang
    Cheng, Bin
    Tao, Xiaoan
    INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (07) : 1548 - 1561